|
Title
|
|
|
|
Compulsory licensing for expensive medicines
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| This is a scientific report drafted in response to a tender by KCE; KCE is an independent research centre that provides scientific advice on topics related to health care to the Belgian government. The report includes a legal analysis and an economic analysis regarding the use of compulsory licensing in the context of very expensive medicines. The legal analysis first provides a descriptive analysis regarding the relevant provisions in Belgian, European and international patent law, on patenting and licensing practices and a more evaluative analysis regarding the use of compulsory licensing, in particular in the medical context. It also contains concrete suggestions and recommendations. The report was drafted at the occasion of a legislative proposal in Belgium to introduce a new compulsory licensing mechanism for such situations. |
| |
|
Language
|
|
|
|
English
| |
|
Source (series)
|
|
|
|
KCE reports ; 356
| |
|
Publication
|
|
|
|
Brussels
:
KCE
,
2022
| |
|
DOI
|
|
|
|
10.57598/R356C
| |
|
Volume/pages
|
|
|
|
200 p.
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|